Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Ashutosh Wechalekar

Ashutosh Wechalekar

MBBS, MD, FRCP, FRCPath, DM
University College London
Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored 9:53
Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored
Ashutosh Wechalekar et al. • 9 Dec 2023
The potential of daratumumab alone or with CyBorD in patients with stage IV AL amyloidosis 0:54
The potential of daratumumab alone or with CyBorD in patients with stage IV AL amyloidosis
Ashutosh Wechalekar • 12 Dec 2022
The safety and efficacy of belantamab mafodotin in AL amyloidosis 1:07
The safety and efficacy of belantamab mafodotin in AL amyloidosis
Ashutosh Wechalekar • 12 Dec 2022
Selecting patients for autologous transplantation in AL amyloidosis: current practice & challenges 2:14
Selecting patients for autologous transplantation in AL amyloidosis: current practice & challenges
Ashutosh Wechalekar • 12 Dec 2022
The role of mass spectrometry in response assessment in patients with AL amyloidosis 1:51
The role of mass spectrometry in response assessment in patients with AL amyloidosis
Ashutosh Wechalekar • 12 Dec 2022
Unmet needs in amyloidosis treatment in the UK 0:47
Unmet needs in amyloidosis treatment in the UK
Ashutosh Wechalekar • 4 Apr 2022
An overview of current and future clinical trials in amyloidosis 1:13
An overview of current and future clinical trials in amyloidosis
Ashutosh Wechalekar • 4 Apr 2022
Highlights from the BSH amyloidosis session 0:43
Highlights from the BSH amyloidosis session
Ashutosh Wechalekar • 4 Apr 2022
TOURMALINE-AL1: ixazomib-dexamethasone for AL amyloidosis 1:36
TOURMALINE-AL1: ixazomib-dexamethasone for AL amyloidosis
Ashutosh Wechalekar
Real-world data in guiding amyloidosis treatment 1:45
Real-world data in guiding amyloidosis treatment
Ashutosh Wechalekar • 31 May 2020
Complete hematological response prior to renal transplant in AL amyloidosis 1:50
Complete hematological response prior to renal transplant in AL amyloidosis
Ashutosh Wechalekar • 1 Jun 2020
Targeting deposits in amyloidosis 0:49
Targeting deposits in amyloidosis
Ashutosh Wechalekar • 5 May 2020
ANDROMEDA: daratumumab & CyBorD for newly diagnosed AL amyloidosis 1:50
ANDROMEDA: daratumumab & CyBorD for newly diagnosed AL amyloidosis
Ashutosh Wechalekar • 16 Jun 2020
Exciting improvements in amyloidosis management and treatment 3:17
Exciting improvements in amyloidosis management and treatment
Ashutosh Wechalekar • 18 Oct 2017
Upcoming amyloidosis clinical trial data to look forward to at ASH 2017 0:42
Upcoming amyloidosis clinical trial data to look forward to at ASH 2017
Ashutosh Wechalekar • 18 Oct 2017
An unmet need: reducing early death in amyloidosis 2:11
An unmet need: reducing early death in amyloidosis
Ashutosh Wechalekar • 18 Oct 2017
The content of VJHemOnc is intended for healthcare professionals